A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma

被引:25
作者
Jakacki, RI
Feldman, H
Jamison, C
Boaz, JC
Luerssen, TG
Timmerman, R
机构
[1] Childrens Hosp Pittsburgh, Div Hematol Oncol, Dept Pediat Hematol Oncol, Pittsburgh, PA 15213 USA
[2] Childrens Hosp Pittsburgh, Child Dev Unit, Pittsburgh, PA 15213 USA
[3] St Vincents Childrens Hosp, Div Pediat Hematol Oncol, Indianapolis, IN USA
[4] Indiana Univ, Med Ctr, Dept Neurosurg, Indianapolis, IN 46204 USA
[5] Indiana Univ, Med Ctr, Dept Radiat Therapy, Indianapolis, IN 46204 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2004年 / 60卷 / 02期
关键词
medulloblastoma; radiation therapy; craniospinal; chemotherapy;
D O I
10.1016/j.ijrobp.2004.03.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Craniospinal irradiation (CSI) is necessary in the treatment of medulloblastoma, although it results in significant long-term sequelae, particularly in young children. We prospectively evaluated the feasibility of giving preirradiation chemotherapy followed by 1800 cGy CSI to young children with localized medulloblastoma. Methods and Materials: Between January 1993 and July 1997, 7 consecutive patients (age, 20-64 months) with MO medulloblastoma were enrolled. After surgical resection, patients received 4 months of multiagent chemotherapy followed by 1800 cGy CSI and 5400 cGy to the posterior fossa. Results: Median follow-up is 8.9 years. No patient developed progressive disease during chemotherapy. One patient developed widespread metastatic recurrence 2 months after completing radiation therapy and died. Two additional patients developed isolated frontal horn relapses 32 and 36 months after initial diagnosis and received further irradiation and chemotherapy. Both of these patients remain alive 7.1 and 3.6 years from the time of recurrence. Four of the six survivors have endocrine deficits. All of the survivors require special assistance in school. Conclusions: Craniospinal irradiation doses of 1800 cGy may not be adequate to prevent exoprimary recurrences. Despite the CSI dose reduction, neuroendocrine and neurocognitive sequelae are substantial. (C) 2004 Elsevier Inc.
引用
收藏
页码:531 / 536
页数:6
相关论文
共 26 条
[1]  
Bergman I, 1997, MED PEDIATR ONCOL, V29, P563
[2]   M4 PROTOCOL FOR CEREBELLAR MEDULLOBLASTOMA - SUPRATENTORIAL RADIOTHERAPY MAY NOT BE AVOIDED [J].
BOUFFET, E ;
BERNARD, JL ;
FRAPPAZ, D ;
GENTET, JC ;
ROCHE, H ;
TRON, P ;
CARRIE, C ;
RAYBAUD, C ;
JOANNARD, A ;
LAPRAS, C ;
CHOUX, M ;
CARTON, M ;
AIMARD, L ;
PHILIP, T ;
BRUNATMENTIGNY, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 24 (01) :79-85
[3]   CEREBELLAR CONTRIBUTIONS TO COGNITION [J].
DAUM, I ;
ACKERMANN, H .
BEHAVIOURAL BRAIN RESEARCH, 1995, 67 (02) :201-210
[4]  
Duffner P K, 1999, Neuro Oncol, V1, P152, DOI 10.1093/neuonc/1.2.152
[5]  
DUFFNER PK, 1985, CANCER-AM CANCER SOC, V56, P1841, DOI 10.1002/1097-0142(19851001)56:7+<1841::AID-CNCR2820561325>3.0.CO
[6]  
2-C
[7]   THE ROLE OF MAINTENANCE THERAPY IN DISSEMINATED TESTICULAR CANCER [J].
EINHORN, LH ;
WILLIAMS, SD ;
TRONER, M ;
BIRCH, R ;
GRECO, FA .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (13) :727-731
[8]   PREIRRADIATION CHEMOTHERAPY INCLUDING 8-DRUGS-IN-1-DAY REGIMEN AND HIGH-DOSE METHOTREXATE IN CHILDHOOD MEDULLOBLASTOMA - RESULTS OF THE M7 FRENCH COOPERATIVE STUDY [J].
GENTET, JC ;
BOUFFET, E ;
DOZ, F ;
TRON, P ;
ROCHE, H ;
THYSS, A ;
PLANTAZ, D ;
STEPHAN, JL ;
MOTTOLESE, C ;
PONVERT, D ;
CARRIE, C ;
RAYBAUD, C ;
BRUNATMENTIGNY, M ;
CHOUX, M ;
PHILIP, T ;
ZUCKER, JM ;
BERNARD, JL .
JOURNAL OF NEUROSURGERY, 1995, 82 (04) :608-614
[9]  
GEYER R, 1998, P ASCO, V17, P526
[10]   MAINTENANCE CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER - LONG-TERM RESULTS OF A RANDOMIZED TRIAL [J].
GIACCONE, G ;
DALESIO, O ;
MCVIE, GJ ;
KIRKPATRICK, A ;
POSTMUS, PE ;
BURGHOUTS, JTM ;
BAKKER, W ;
KOOLEN, MGJ ;
VENDRIK, CPJ ;
ROOZENDAAL, KJ ;
PLANTING, AST ;
VANZANDWIJK, N ;
TENVELDE, GJM ;
SPLINTER, TAW .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1230-1240